March/April 2012 - Volume 35 - Issue 2 - Contributor Index

Alphabetical Search
D
E
O
Q
U
X
Y

Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity and Disability at Baseline: Real-Life Data From a Swiss Cohort

Kallweit, Ulf; Jelcic, Ilijas; Braun, Nathalie; More

Clinical Neuropharmacology. 35(2):77-80, March/April 2012.

Author:
Celebi, Arif MD

Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity and Disability at Baseline: Real-Life Data From a Swiss Cohort

Kallweit, Ulf; Jelcic, Ilijas; Braun, Nathalie; More

Clinical Neuropharmacology. 35(2):77-80, March/April 2012.

Effect of 12-Week Administration of 20-mg Long-Acting Methylphenidate on Glu/Cr, NAA/Cr, Cho/Cr, and mI/Cr Ratios in the Prefrontal Cortices of School-Age Children in Indonesia: A Study Using 1H Magnetic Resonance Spectroscopy (MRS)

Wiguna, Tjhin; Guerrero, Anthony P.S.; Wibisono, Sasanto; More

Clinical Neuropharmacology. 35(2):81-85, March/April 2012.

Author:
Gursoy, Esra MD

Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity and Disability at Baseline: Real-Life Data From a Swiss Cohort

Kallweit, Ulf; Jelcic, Ilijas; Braun, Nathalie; More

Clinical Neuropharmacology. 35(2):77-80, March/April 2012.

Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity and Disability at Baseline: Real-Life Data From a Swiss Cohort

Kallweit, Ulf; Jelcic, Ilijas; Braun, Nathalie; More

Clinical Neuropharmacology. 35(2):77-80, March/April 2012.

Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity and Disability at Baseline: Real-Life Data From a Swiss Cohort

Kallweit, Ulf; Jelcic, Ilijas; Braun, Nathalie; More

Clinical Neuropharmacology. 35(2):77-80, March/April 2012.

Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity and Disability at Baseline: Real-Life Data From a Swiss Cohort

Kallweit, Ulf; Jelcic, Ilijas; Braun, Nathalie; More

Clinical Neuropharmacology. 35(2):77-80, March/April 2012.

Author:
Raoux, Aude MD

Effect of 12-Week Administration of 20-mg Long-Acting Methylphenidate on Glu/Cr, NAA/Cr, Cho/Cr, and mI/Cr Ratios in the Prefrontal Cortices of School-Age Children in Indonesia: A Study Using 1H Magnetic Resonance Spectroscopy (MRS)

Wiguna, Tjhin; Guerrero, Anthony P.S.; Wibisono, Sasanto; More

Clinical Neuropharmacology. 35(2):81-85, March/April 2012.

Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity and Disability at Baseline: Real-Life Data From a Swiss Cohort

Kallweit, Ulf; Jelcic, Ilijas; Braun, Nathalie; More

Clinical Neuropharmacology. 35(2):77-80, March/April 2012.

Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity and Disability at Baseline: Real-Life Data From a Swiss Cohort

Kallweit, Ulf; Jelcic, Ilijas; Braun, Nathalie; More

Clinical Neuropharmacology. 35(2):77-80, March/April 2012.

Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity and Disability at Baseline: Real-Life Data From a Swiss Cohort

Kallweit, Ulf; Jelcic, Ilijas; Braun, Nathalie; More

Clinical Neuropharmacology. 35(2):77-80, March/April 2012.

Effect of 12-Week Administration of 20-mg Long-Acting Methylphenidate on Glu/Cr, NAA/Cr, Cho/Cr, and mI/Cr Ratios in the Prefrontal Cortices of School-Age Children in Indonesia: A Study Using 1H Magnetic Resonance Spectroscopy (MRS)

Wiguna, Tjhin; Guerrero, Anthony P.S.; Wibisono, Sasanto; More

Clinical Neuropharmacology. 35(2):81-85, March/April 2012.

Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity and Disability at Baseline: Real-Life Data From a Swiss Cohort

Kallweit, Ulf; Jelcic, Ilijas; Braun, Nathalie; More

Clinical Neuropharmacology. 35(2):77-80, March/April 2012.

Show: